Pharma Focus Asia

Enhanced Healthcare Partners Announces Investment in SCA Pharmaceuticals

Friday, October 06, 2017

Enhanced Healthcare Partners, a private equity firm focused exclusively on investing in the healthcare industry, has announced its investment in SCA Pharmaceuticals ("SCA"), a sterile compounding leader specializing in preparing sterile pharmaceuticals customized for hospitals, pharmacies and healthcare facilities nationwide. The terms of the transaction were not disclosed.

SCA was founded in 2010 and over the past seven years has become a nationally recognized FDA 503B outsourcing facility specializing in providing the highest quality sterile admixture services and pre-filled oral syringes to hospital pharmacies. SCA provides these services across all therapeutic areas of pharmacy including critical care, labor and delivery, anesthesia, and pain management and maintains a wide portfolio of products, including unit dosed oral syringes and drug shortage medications.

EHP is a healthcare-focused private equity firm committed to partnering with family and founder run businesses. The Enhanced team has raised more than $700 million in committed capital, completed investments in sixteen companies and closed more than 80 add-on acquisitions driving more than 60% compound annual growth in the active portfolio.  EHP professionals have more than 100 years of combined experience investing in healthcare companies and possess strong relationships and knowledge within the industry.

"The sterile compounding industry has experienced unprecedented growth amidst rising production complexities as more hospitals, pharmacies and healthcare facilities require these products and simultaneously demand the highest quality of sterility assurance," said Matt Thompson, Principal at Enhanced Healthcare Partners. "SCA is a recognized leader in the field with an uncompromising commitment to quality and compliance.  We are excited to work with the company's outstanding management team to support the execution of their strategic growth and development plan."

"To accomplish our ambitious goals, we knew we needed a best in class investment partner," said Milton Boyer, Chief Executive Officer of SCA. "EHP has deep experience working with innovative healthcare companies and we are thrilled to partner with their accomplished team during such an exciting phase in the company's growth. With EHP's support, SCA is primed to continue its rapid expansion and solidify itself as an industry leader."

EHP's investment enables SCA to accelerate its growth strategy, including opening a new 90,000 square-foot manufacturing facility in Windsor, Connecticut.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024